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Celiac Disease: Current and Investigational Therapies
and the Role of the Pharmacist
Sarah Turley, fifth-year pharmacy student from Hilton Head Island, S.C.; Gabriella Gegenheimer, fourth-year pharmacy
student from Upper Arlington, Ohio; Emily Blum, fifth-year pharmacy student from Buffalo, N.Y.;
Erin Petersen, PharmD '11, BCPS, assistant professor of pharmacy practice
This knowledge-based activity is targeted for all pharmacists
and is acceptable for 1.0 hour (0.1 CEU) of continuing
education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.

ACPE Universal Activity Number (UAN): 0048-0000-14-032-HO 1-P
Objectives
After completion of this program, the reader should be able
to:
1. Explain the etiology, patient presentation and
diagnosis of Celiac disease.
2. Discuss the current therapy for Celiac disease,
highlighting the gluten-free diet.
3. Identify investigational pharmacotherapeutic options
for Celiac disease.
4. Define the pharmacist's role in patient education
and counseling for Celiac disease.
Abstract
Celiac disease is a genetically-linked autoimmune disease
which affects the gastrointestinal tract. It is an inflammatory
reaction to ingested gluten-containing substances that produces the most frequent symptoms of abdominal pain, bloating and intermittent or chronic diarrhea. Diagnosis can be
made by blood testing for specific IgA autoantibodies and a
confirmation duodenal biopsy to look for the characteristic
scalloping and villous atrophy that occurs in response to the
inflammation. A gluten-free diet, until recently, was the only
treatment available and continues to be the mainstay of
treatment Newer adjunct therapies to dietary management
include larazotide acetate, peptidases, the use of parasite
Necator americanus, a desensitizing vaccine, polymeric binders, cytokine antagonists, tissue transglutaminase inhibitors,
probiotics and anti-inflammatory therapy. This review will
outline the potential of each of these therapies and discuss
the role of the pharmacist in assisting patients with Celiac
disease.
Introduction
In recent years, Celiac disease has emerged in society as a
common, genetically-linked condition affecting the gastrointestinal (GI) system. It is an autoimmune disease that leads to
gastrointestinal side effects as a result of ingestion of glutencontaining substances. The disease has risen in prevalence as
physician awareness and diagnosis of the condition has increased. Still, many patients live with the condition and deal
with the symptoms while remaining undiagnosed. Celiac
disease can negatively affect patient quality of life for a

multitude of reasons. These include physical discomfort associated with the disease as well as the inconvenience of
maintaining a gluten-free diet, which is currently the only
treatment option.
Several new pharmacological therapies and drug targets are
under investigation for relief of symptoms and may be viable
options for use as adjunct therapy in Celiac disease patients.
While none of these products are currently on the market,
they have the potential to be realistic additions to therapeutic regimens in the future. Pharmacists have an important
role in counseling patients about the disease and how to
manage symptoms. They will be sought out as drug experts
for the disease state, as well as excellent resources for information about gluten-free foods and medications. The number
of patients with Celiac disease will only continue to increase,
and it is important to be knowledgeable about the disease
state and incorporate patient counseling and education into
pharmacists' everyday practice.
Disease Overview
Celiac disease is an increasingly prominent disease state that
is highly linked to genetic factors. Such genetic factors are
linked to mutations on the human leukocyte antigen (HLA)
Class II genes, specifically haplotypes HLA-DQ2 and HLADQ8, found on the 6p21 chromosome.1 Genetic mutations are
the most predominant factor in eliciting the immunemediated response to gluten, as 4 to 12 percent of Celiac disease patients have a first degree relative also suffering from
this disease state. 2 It is important to note, however, that 30 to
40 percent of Caucasians have these HLA mutations with
only 2 to 5 percent of carriers presenting with Celiac disease
signifying that genetic mutations are necessary for disease
presentation but are not the sole cause of Celiac disease.1
While genetic predisposition is important to consider, other
factors may also contribute to the development of Celiac disease. These include environmental factors, such as a past
enteric infection or patients who are exposed to gluten prior
to 4 months of age. 1 Furthermore, patients who suffer from
other immune-mediated genetic disorders that affect the GI
tract, such as Crohn's disease and ulcerative colitis, are more
susceptible than other individuals to develop this disease state.2
Celiac disease is classified as an immune-mediated disorder,
as its symptomatic presentation is due to gluten, which triggers immunological reactions. 3 These immunological reactions stimulate an autoimmune response by the cells of the
GI tract, stimulating inflammatory mediators. 4 Inflammatory
mediators present in Celiac disease may lead to the opening
of tight junctions in the intestinal epithelium. Tight junctions
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regulate fluid and molecule passage between intestinal
epithelial cells to the lamina propria. Proteins known as
zonula occludins also regulate the structure and function of
the cellular cytoskeleton by linking tight junctions with the
actin network. When the tight junctions are not functioning
properly, gluten (or gliaden) peptides gain access across the
intestinal epithelium and are then modified by the enzyme,
tissue transglutaminase (tTG). 1· s T-cells will then present the
modified gluten as an antigen via HLA-DQZ and HLA-DQB
proteins. Gluten presentation then initiates both humoral
and cell-mediated immune responses, leading to a temporary
and reversible remodeling of intestinal mucosa, including
scalloping of the small intestine mucosa and villous atrophy
leading to malabsorption and symptoms such as abdominal
pain, bloating and diarrhea.1

Patient Presentation
Celiac disease is prevalent across ethnicities, ages and genders with increasing prevalence not only in the pediatric
population but also the adult population. Symptoms present
in 1 percent of the U.S. population but may be undiagnosed in
up to 85 to 90 percent of cases.1.2 Celiac disease classically
presents with symptoms related to malabsorption of gluten,
which can include but are not limited to abdominal pain,
bloating and intermittent or chronic diarrhea.1.3 Chronic diarrhea is due to changes in the gastrointestinal wall leading
to malabsorption of gluten, and can cause dehydration,
weight loss and muscle wasting. Further signs of Celiac disease include anemia, most commonly iron-deficiency, due to
malabsorption. Vitamin D deficiency and Vitamin 812 deficiency can also be signs of Celiac disease. 1 Of those patients
with Celiac disease, 15 to 25 percent present with the nontraditional symptom of dermatitis herpetiformis, a rash that
occurs without the accompaniment of GI symptoms.2 The
inflammatory process associated with dermatitis herpetiformis results from lgA deposition and neutrophil accumulation, which leads to vesicle formation, producing a rash commonly found on the elbows, knees and buttocks, an important clinical observation for patients with suspected Celiac
disease.2
Due to similar GI symptoms across various GI disorders, it is
important to note that some patients who suffer from Celiac
disease also have a secondary disorder including lactose intolerance or inflammatory bowel disease (IBD). 1 Those patients suffering from autoimmune diseases including type 1
diabetes mellitus and autoimmune thyroid disorder may be
more likely to present with Celiac disease and should be
tested regardless of symptom presentation.1,3 Celiac disease
patients may also be more likely to have other immunemediated diseases that affect the GI tract, such as Crohn's
disease or ulcerative colitis.2 Patients who have been diagnosed with lactose intolerance or diarrhea-predominant IBD
and have not showed improvement should consider being
tested for Celiac disease. The diagnosis process is an important step for patients because, although death is not a common outcome of this disease state, patients with multiple
disease states are at an increased risk for complications such
as vitamin deficiencies, malnutrition, ulcerative jejunitis,
T-cell lymphoma and an overall decrease in quality oflife.1
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Diagnosis
Diagnosis is vital for patients suffering from Celiac disease
due to a fourfold increase in mortality in patients with an
untreated disease state. 7 Patients who present with Celiac
disease symptoms should be screened via a blood test or intestinal biopsy. 2 Furthermore, asymptomatic patients who
have a first-degree or second-degree relative with confirmed
Celiac disease, type 1 diabetes, autoimmune thyroid disorders, rheumatoid arthritis or GI associated autoimmune disorder should be tested for Celiac disease. The first step for
suspected patients is testing a blood sample for specific IgA
autoantibodies via immunofluorescence. For patients undergoing a blood sample, it is important to eat foods containing
gluten prior to testing, otherwise the patient may receive a
false negative result for Celiac disease.1 Those patients suffering from Celiac disease will present with elevated IgA to
tTG or epithelial membrane antigen (EMA).2 Most likely, tTG
IgA will be screened due to its cost efficiency and comparable
accuracy to the EMA IgA test. Another method of testing is
via an upper endoscopy with duodenal biopsies to look for
scalloping of the folds or cracking of the small intestine as
well as villous atrophy linked to inflammatory changes. Due
to the biopsy expense, this step in diagnosis should be suggested after blood testing in order to confirm the disease
state. 1
Treatment
Treatment should be started once Celiac disease is suspected.
Currently, a gluten-free diet is the only therapeutic option for
patients with Celiac disease. Gluten can be found in wheat,
barley and rye containing products. Due to crosscontamination in manufacturing, it is very difficult to completely avoid the irritating substances. Due to the difficulty
finding specifically gluten-free foods, many Celiac disease
patients are exposed to low levels of gluten on a regular basis. Also, many medications have inert ingredients that contain gluten, making total avoidance even more difficult. It is
estimated that 30 to 50 percent of patients are not able to
strictly adhere to the proper diet, and at any given time 50
percent of all Celiac disease patients have an active disease
state. 4 A gluten-free diet will aid in the healing of intestinal
mucosa.1 Those patients who suffer from dermatitis herpetiformis can treat the rash with dapsone, which inhibits
neutrophil recruitment and downstream inflammatory processes, if the rash does not resolve after committing to a gluten-free diet,1.6 About 90 percent of patients will present
with no symptoms after five years of a gluten-free diet, and
almost all patients will experience some relief from symptoms immediately after beginning the diets Those patients
who follow a strict gluten-free diet have a better, long-term
quality of life due to greater and more consistent relief, as
well as an overall enhanced state of health (i.e. mental health,
pain, vitality, social function, physical function).9 Overall, relief of Celiac disease symptoms is due to a decrease in lgA
specific autoantibody production via removal of the antigen
(gluten).10 Patients continuing to suffer from symptoms can
more rigorously utilize pharmacological agents to treat
symptoms related to deficiencies in Vitamin 812, Vitamin D
and folic acid. Furthermore, nonsteroidal anti-inflammatory
agents (NSAIDs) and anti-diarrheals can be used for symp-
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tom management. If symptoms persist after symptom management and strict adherence to a gluten-free diet, it is recommended that the patient revisit his or her doctor to determine if the patient is suffering from an additional disorder. 11

New Pharmacological Therapies
New pharmacological therapies are in development to treat
Celiac disease as an adjunct to the gluten-free diet. These
novel therapies are necessary to increase the quality of life in
patients who are still exposed to gluten even with best efforts to avoid the offending agent. 4 Currently, many different
methods of therapy have been investigated, including larazotide acetate, peptidases, the use of parasite Necator americanus, a desensitizing vaccine, polymeric binders, cytokine
antagonists, tissue transglutaminase inhibitors, probiotics
and anti-inflammatory therapy.4.12,13
Cellular exposure to gluten can be reduced by use of larazotide acetate, a therapy in development. Larazotide acetate
(ALBA Therapeutics) acts on the cytoskeleton to prevent
opening of tight junctions and reduce gluten transport into
cells from the intestinal lumen.4 It also promotes redistribution and reorganization of zonula occludins and other proteins that associate with actin in the cytoskeleton. ALBA
Therapeutics conducted a study testing the effects of larazotide acetate on junction assembly in kidney and intestinal
cells. This study was conducted in vitro and showed promising results through several mechanisms including promotion
of tight junction assembly, actin reorganization for stronger
assembly of tight junctions, GTPase regulation of the cytoskeleton and inhibition of tight junction disassembly. 5 Improved tight junctions will lessen intestinal cell exposure to
gluten, which can reduce inflammatory reactions in the GI
tract.
Furthermore, in a randomized, placebo-controlled study by
Kelly et al., the efficacy of larazotide acetate was assessed in
patients receiving small amounts of gluten daily (2.7 g of gluten, equivalent to one slice ofbread) .14 The primary endpoint
of the study was a measure of intestinal permeability known
as the lactulose-to-mannitol (LAMA) ratio. Patients with Celiac disease have an increased LAMA ratio. Results showed
no statistical differences in LAMA ratio between placebo and
treatment groups; however, the study acknowledged flaws in
timing of LAMA assay and outpatient testing that may have
affected results. Secondary endpoints included measures of
serum anti-tTG IgA levels and showed the greatest increase
in the placebo group from zero to six weeks, in which 30 percent of patients in the group seroconverted. Serum concentrations of the treatment group remained below levels that
qualify a positive antibody test.14 When compared to placebo,
the treatment groups showed significantly lower anti-tTG
IgA levels (1 mg dose p=0.010, 4 mg dose p=0.005, 8 mg dose
p=0.025). There was also evidence to suggest that patients
treated with larazotide acetate had fewer gastrointestinal
side effects when compared to placebo. However, only the
1 mg daily dose of larazotide acetate reached statistically
significant lower scores in patient-reported abdominal pain,
indigestion and diarrhea versus placebo by the end of the
treatment period (p=0.017).14

Another randomized, double-blinded, placebo-controlled
study by Leffler et al. also had a primary endpoint of changes
in LAMA ratio as well as measures of serum tTG antibodies.
Results were similar to the Kelly et al. study, with the
changes in LAMA ratio not reaching statistical significance.
However, serum tTG did not reach statistically lower levels
in this study. This study did show a significant difference in
severity of gastrointestinal side effects between the patients
receiving larazotide acetate with a gluten challenge versus
the gluten challenge control group as evidenced by the Gastrointestinal Symptom Rating Scale (p<0.05).15 Results from
all three studies suggest that larazotide acetate has the benefit of inhibiting the opening of tight junctions in intestinal
cells. Larazotide acetate may in the future have the possible
therapeutic use as an adjunct to a gluten-free diet and relief
of some symptoms of Celiac disease.5.11,15
Another novel drug therapy for the treatment of Celiac disease is the use of oral peptidases to hydrolyze gluten polypeptides. In this form, the gluten molecules can no longer
stimulate damaging intestinal immune responses. Alvine
Pharmaceuticals has developed ALV003, a combination of
two gluten-sensitive peptidases. The company DSM has also
developed a peptidase (AN-PEP), and a third is being tested
by Stanford University. A phase I clinical trial showed that
the use of ALV003 for pretreatment of gluten ingestion in
Celiac disease patients caused a decrease in activation of immunological markers, as well as benefit in breaking down
high gluten-containing foods. 4 However, this trial was underpowered and did not achieve statistically significant values
for serology or symptom improvement. AN-PEP has showed
less success in reaching significant endpoints in trials. However, AN-PEP is being considered as a food supplement as it
is particularly active at degrading gluten in the stomach. One
drawback of peptidase use is the susceptibility of these peptides to the acidic conditions of the stomach, and modification with polymer substitutes has been considered. 12 Use of
oral peptidases has been one of the most investigated therapeutic options for the treatment of Celiac disease; however,
its role in clinical practice has yet to be determined.
The use of the parasite Necator americanus is another investigational therapy for Celiac disease patients. Trials are underway to test whether or not this helminth infection can
attenuate the autoimmune intestinal inflammation associated with Celiac disease.16 The theory behind this therapy is
derived from the hygiene hypothesis: the notion that increasing numbers of allergic and autoimmune disorders in developed countries may be associated with the decrease of infectious diseases present in society.16,17 In a prospective, placebo-controlled, randomized, double-blind trial by Daveson
et al., Necator americanus infection in Celiac disease patients
was evaluated with primary endpoints of duodenal histology
scores (for intestinal damage) and systemic interferongamma levels (for inflammation). Inoculation with the worm
was instituted in patients who subsequently underwent a
gluten challenge. A placebo group underwent the same gluten challenge without the worm for comparison. Results
showed no statistical difference in duodenal histology scores
or interferon-gamma levels between the infected and control
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groups. This study in particular shows that helminth infection may not alleviate the need for a gluten-free diet in Celiac
disease.16 Limited studies using this therapy have been investigated at this time, and currently helminth infection therapy
is not seen as a therapeutic option used in clinical practice.
Desensitization through the use of a Celiac disease-specific
vaccination is also an investigational therapy. The biotechnology company ImmuSanT has developed a vaccine, Nexvax2®, which contains immunogenic gluten peptides from
wheat, barley and rye. The vaccine was developed with the
goal of restoring gluten-tolerance in Celiac disease patients
through use as an immunotherapeutic and prophylactic
agent,12 A phase I study has evaluated the safety and efficacy
of weekly intradermal injections of Nexvax2® compared to
placebo by measuring immune T-cell response. The study's
formally written publication has not yet been released.
Thirty-four HLA-DQ2+ Celiac disease patients were randomized to four treatment groups (receiving 9 mcg, 30 mcg, 60
mcg and 90 mcg of Nexvax2® weekly for three weeks) and a
placebo group (receiving saline injections on the same schedule). Results showed that the incidence of GI side effects was
similar in the treatment and placebo groups. In the treatment
group, immunological responses to Nexvax2® were similar to
acute exposure to oral gluten (gluten ingestion) in the mobilization of gluten-specific T-cells,IB.19 Patients receiving the
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vaccine were found to have interferon-gamma-producing
Nexvax2®-specific T-cells, which validates the bioactivity of
the vaccine through immunological response. The hope is
that through repeated vaccinations, a Celiac disease patient
will develop tolerance to the immunogenic gluten peptides
and be able to incorporate small amounts of gluten into his
or her diet.12 Thus far, data are extremely limited on the efficacy of such a therapy and more trials are needed. This may
be a viable option in the future and an additional agent that
could improve the quality of life of Celiac disease patients.
Many new therapeutic options for the treatment of Celiac
disease are in very early stages of development. It may be
some time before viable options are commercially available
or before they become standards of practice for treatment.
However, the amount of research and development into
pharmacological therapies for Celiac disease is promising,
and awareness and knowledge of these therapies are critical
for pharmacists to be prepared for potential changes in Celiac disease state management in the future.

Pharmacists' Role
Pharmacists have a key role in improving the quality of life
for patients suffering from Celiac disease and thus are best
able to share important medication-nutrition and nutritiondisease state interactions with patients.20 Resources for pa-

Table 1. Drug Excipients That are Safe or Require Further Investigation in Celiac Disease Patients21.22

Gluten-free Ingredients

Ingredients Needing Further Investigation (if source not specified)

Benzyl alcohol
Cellulose
Cornstarch

Caramel coloring

Croscarmellose sodium

Dextrate

Fructose

Dextrimaltose

Gelatin

Dextrin

Glycerin

Maltodextrin

Lactose

Modified starch

Mannitol

Potato

Polysorbates

Pregelatinized modified starch

Silicon dioxide

Pregelatinized starch

Sodium lauryl sulfate

Sodium starch glycolate

Stearates

Starch

Sucrose

Tapioca

Titanium dioxide
Note: This chart is not an exhaustive list of gluten-free or gluten-containing ingredients used in medications. If there is ever
a question about a specific medication ingredient, the drug manufacturer should be contacted for inquiry.
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tient advising can be found through the National Foundation
for Celiac Awareness (NFCA) at www.celiaccentral.org. Patient resources and brochures include information regarding
what is Celiac disease, the choice to be gluten free, Celiac disease and women's health, and a Celiac disease symptoms
checklist.21 This information is free and available for pharmacists to provide to patients and will afford patients a better
understanding of the disease.
Another important concern for pharmacists is the identification of gluten in various medications and over-the-counter
products including vitamins, supplements and lip balms.
These less obvious sources of gluten have been found to exacerbate patients' symptoms and should be monitored. 1 It is
important for pharmacists to be aware of the excipients present in medications, especially because generic medications
are not required to use the same excipients as the brand
name medication. Likewise, not all generics are equal, and
even two generics for the same medication may not contain
the same excipients. Table 1 provides a list of excipients that
are gluten-free and those ingredients that may need further
investigation (if source not specified) to ensure safety. A
drug manufacturer should be contacted if the pharmacist or
patient is unsure of the excipient used, the source of the excipient or the possibility of cross contamination. As medication experts, pharmacists should know how to obtain this
information for an inquiring patient.22 Pharmacists and patients can find extensive lists of brand and generic prescription medications as well as over-the-counter medications
that do not contain gluten at glutenfreedrugs.com. This website is kept up to date by a clinical pharmacist who continually updates the information for public access.23
Pharmacists are also an accessible resource for patients to
approach about gluten-free food options and healthy living
while on this restricted diet. It is important for pharmacists
to counsel on the extra cost associated with preparing
gluten-free foods and for patients to consider this in their
budget. Equally important is directing patients to the aforementioned resources about Celiac disease for additional assistance. In order to help those patients on a gluten-free diet,
labeling requirements have been added that mandate food
labels to identify wheat and other common food allergens, as
a result of a rising prevalence of patients suffering from Celiac disease and gluten intolerance. Additional requirements
include regulations by the U.S. Food and Drug Administration
(FDA) to control rules for the use of the term "gluten-free" on
products. The FDA has standardized their definition of
"gluten-free" such that foods containing this term or claiming
to contain "no gluten," "free of gluten" and "without gluten"
must contain less than 20 parts per million of gluten, an
amount not seen to harm patients with Celiac disease. 24
Conclusion
Celiac disease is gammg more and more recognition by
health care professionals as the prevalence of the disease
state increases. It is a genetically-linked disease whose diagnosis and treatment can lead to improved patient quality of
life. While current practice only champions the gluten-free
diet for treatment, newer investigational pharmacotherapy

may emerge in the near future. Pharmacists will remain an
important resource for patient education about Celiac disease. Pharmacists will be called upon to investigate medications and foods that may be appropriate or inappropriate in
Celiac disease. Patient care is always a number one goal, and
knowledge of this condition will allow pharmacists to be a
primary resource for the treatment of Celiac disease.
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Assessment Questions
Etiology
l. Development of Celiac disease is genetically linked to
which two haplotypes found on the mutated HLA Class II
gene?
A. HLA-DQ2
B. HLA-DQB
c. HLA-DQ21
D. Both A and B
E. Both A and C

lnvestigational Therapy
7. Larazotide acetate is a novel therapeutic option for
Celiac disease whose mechanism of action includes:
A. Manipulation of the cytoskeleton to facilitate
tight junction opening
B. Actin reorganization for better assembly
C. Inhibition of tight junction disassembly
D. Both A and B
E. Both B and C

Patient Presentation
2. Symptoms of Celiac disease include all of the following
EXCEPT:
A. Abdominal pain
B. Bloating
C. Cyanosis
D. Diarrhea
E. Iron deficiency

8.

Therapeutic use of gluten peptidases show the
advantage of:
A. Decrease in activation of immunologic markers
B. Use as monotherapy for treatment of Celiac
disease
C. Gluten peptides are unsusceptible to acidic
conditions in the stomach
D. All of the above

Diagnosis
3. What counseling should be provided to a patient who is
having a blood test for Celiac disease diagnosis?
A. Eat gluten prior to the blood test
B. Do not eat gluten prior to the blood test
C. Fast for 12 hours prior to the blood test
D. Exercise one hour prior to the blood test
E. None of the above

9.

The desensitization vaccine, Nexvax2®:
A. ls currently on the market and available for
patient use
B. Targets three gluten peptides found in wheat,
barley and rye
C. Has an increased incidence of GI side effects
compared to ingestion of gluten
D. Recently completed phase III clinical trials

Treatment
4. Relief of symptoms in Celiac disease patients is rooted in
a decrease in which autoantibody?
A. IgA
B. IgD
C. lgE
D. IgG
E. All of the above

Pharmacists' Role
10. If a patient has a question about gluten in medications, a
pharmacist should:
A. Tell the patient to check the medication
ingredients on their own.
B. Explain that all medications are gluten-free and
they should not worry.
C. Contact the drug manufacturer about
questionable ingredients or with concerns
about cross-contamination.
D. Assure patients that a small amount of gluten
will not effect their condition.

5.

6.

After five years of following a gluten-free diet, about
_ _ of Celiac disease patients will be completely
symptom free.
A. 1%
B. 10%
c. 25%
D. 50%
E. 90%
Which of the following is NOT true about following a
strict gluten-free diet?
A. Following a gluten-free diet will improve patient
quality of life.
B. Patients who follow a gluten-free diet and no
longer have symptoms do not need to visit their
doctor for reevaluation.
C. Patients who follow a gluten-free diet have a
better health status.
D. Patients who follow a gluten-free diet have a
greater and more consistent relief of symptoms.

~.

Ohio Northern University is accredited by the
Accreditation Council for Phannacy Education as a
provider of continuing pharmacy education. This
program is eligible for credit until 02/25/2017.

To receive continuing education credit for this program, you
must answer the above questions and fill out the evaluation
form. Please visit www.onu.edu/pharmacy to enter the
required information. Please allow two to three weeks for
electronic distribution of your continuing education certificate, which will be sent to your valid email address in PDF
format.

To receive continuing education credit for this program, visit www.onu.edu/pharmacy/CE OR fill out the form below
including your indicated answers to the assessment questions and return to:

Office of Continuing Education at the Raabe College of Pharmacy
Ohio Northern University
525 South Main Street
Ada, Ohio 45810

Program Title: Celiac Disease: Current and Investigational Therapies and the Role of the Pharmacist
UAN: 0048-0000-14-032-HOl-P CEUs: 0.1
All information must be printed CLEARLY to ensure accurate record keeping for attendance and the awarding of
continuing education credit. Certificates will be distributed as a PDF document to a valid email address.

Name:
Address:
City:

State:

Phone:

Email:

Pharmacy License #:

State:

Zip:

y

ONU Alumni?

The program objectives were clear.

N

1

2

3

4

5

Explain the etiology, patient presentation and diagnosis
of Celiac disease.

1

2

3

4

5

Discuss the current therapy for Celiac disease, highlighting the gluten-free diet.

1

2

3

4

5

Identify investigational pharmacotherapeutic options
for Celiac disease.

1

2

3

4

5

Define the pharmacist's role in patient education and
counseling for Celiac disease.

1

2

3

4

5

The program met your educational needs.

1

2

3

4

5

Content of the program was interesting.

1

2

3

4

5

Material presented was relevant to my practice.

1

2

3

4

5

The program met the stated goals and objectives:

Comments/Suggestions for future programs:

Thank you!
Answers to Assessment Questions-Please Circle Your Answer
1.

ABCDE

4. A B C D E

7.

A B C D E

2.

A B C D E

5.

A B C D

8.

A B C D

3.

A B C D E

6.

A B C D

9.

A B C D

E

Any questions/comments regarding this continuing education program can
be directed to Lauren Hamman, Advanced Administrative Assistant for the
Office of Continuing Education (email: l-hamman@onu.edu, phone 419772-2280).

~1

10. A B C D

Ohio Northern University is accredited by the
Accreditation Council for Pharmacy Education as a
provider of continuing pharmacy education. This
program is eligible for credit until 02/25/2017.

